Early Predictors of Anemia in Patients With Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a (40KD) Plus Ribavirin

Reau, Nancy; Hadziyannis, Stephanos J.; Messinger, Diethelm; Fried, Michael W.; Jensen, Donald M.
August 2008
American Journal of Gastroenterology;Aug2008, Vol. 103 Issue 8, p1981
Academic Journal
OBJECTIVE: Adherence to ribavirin is one factor that is critically important in the treatment of hepatitis C virus infection. However, ribavirin can be associated with clinically significant hemolytic anemia resulting in dose modifications in up to one-quarter of patients. Currently, baseline predictors of considerable anemia are not sufficiently discriminating for routine therapeutic intervention. The objective of this analysis was to elucidate baseline and on-treatment factors predictive of a considerable hemoglobin drop at week 4. METHODS: Multivariate logistic regression analysis was used to explore possible predictors for considerable hemoglobin decline (≥2.5 g/dL) at week 4 among patients receiving peginterferon alfa-2a (40KD) and ribavirin (1,000/1,200 mg/day). RESULTS: A total of 555 patients were included in this analysis. At week 4, 236 patients exhibited a ≥2.5 g/dL decrease in hemoglobin. By regression analysis the most important independent variables associated with a decrease in hemoglobin of ≥2.5 g/dL were baseline creatinine clearance ( P= 0.0003) and a rapid decline in hemoglobin of ≥1.5 g/dL at week 2 ( P < 0.0001). Considerable hemoglobin decreases at week 4 were also significantly associated with early ribavirin dose reductions and a lower cumulative daily dose of ribavirin. CONCLUSION: Patients with impaired renal function may be at an increased risk of ribavirin-related anemia and should be monitored accordingly. Furthermore, a hemoglobin drop of ≥1.5 g/dL by week 2 was an excellent early predictor for subsequent considerable hemoglobin decreases and might be used to identify candidates for early intervention against anemia in order to help maintain ribavirin dosing and avoid suboptimal exposure.


Related Articles

  • Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. Shintaro Takaki; Akihito Tsubota; Tetsuya Hosaka; Norlo Akuta; Takashi Someya; Masahiro Kobayashi; Lumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Sarroh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada // Journal of Gastroenterology;2004, Vol. 39 Issue 7, p668 

    Background. Recent studies indicate that combination therapy with ribavirin and interferon alfa2b (IFNΑ2b) is effective for chronic hepatitis C virus (HCV) infection. However, reversible hemolytic anemia is a common side effect of this therapy. Methods. We determined those factors that...

  • Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Oze, Tsugiko; Hiramatsu, Naoki; Kurashige, Nao; Tsuda, Natsuko; Yakushijin, Takayuki; Kanto, Tatsuya; Takehara, Tetsuo; Kasahara, Akinori; Kato, Michio; Yoshihara, Harumasa; Katayama, Kazuhiro; Kubota, Shinji; Hijioka, Taizo; Ishibashi, Kazunobu; Oshita, Masahide; Hagiwara, Hideki; Haruna, Yoshimichi; Mita, Eiji; Tamura, Shinji; Hayashi, Norio // Journal of Gastroenterology;Sep2006, Vol. 41 Issue 9, p862 

    The aim of this study was to examine the factors correlated with the progression of ribavirin-induced hemolytic anemia in patients with chronic hepatitis C treated by interferon and ribavirin combination therapy. This study was conducted on 505 patients by the Osaka Liver Disease Study Group. A...

  • Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C. Al-Bawardy, Badr; Kim, W. Ray; Poterucha, John J.; Gross, John B.; Charlton, Michael R.; Larson, Joseph J.; Colby, Colin L.; Canterbury, Kathy; Warner, Jennifer; Therneau, Terry M. // Mayo Clinic Proceedings;May2014, Vol. 89 Issue 5, p595 

    Objective: To examine the effectiveness and tolerability of triple therapy with pegylated interferon (p-IFN), ribavirin (RBV), and telaprevir in patients with chronic hepatitis C receiving treatment in an academic practice setting and in a more clinically diverse population compared with...

  • Immunological markers predicting outcome in patients with hepatitis C treated with interferon-α and ribavirin. Lee, Silvia; Macquillan, Gerry C; Keane, Niamh M; Flexman, James; Jeffrey, Gary P; French, Martyn Ah; Brochier, Jean; Price, Patricia // Immunology & Cell Biology;Aug2002, Vol. 80 Issue 4, p391 

    Summary Type 1 (T1) cytokine responses are required for the clearance of hepatitis C virus by cytotoxic T lymphocytes, but can promote liver damage. Interferon-α (IFNα) can be expected to promote T1 cytokine responses, so treatment outcome may depend on the T1/T2 cytokine environment and...

  • Review: Interferon-α plus ribavirin improves the virologic response in chronic hepatitis C. Reichen, Juerg // ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p17 

    Provides information on a study that examined whether interferon-α plus ribavirin more effective than interferon-α alone for improving hepatitis C virologic response and liver-related morbidity and mortality in patients with chronic hepatitis C. Data sources; Study selection; Main...

  • HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Romero-Gómez, Manuel; González-Escribano, María Francisca; Torres, Belén; Barroso, Natalia; Montes-Cano, Marco Antonio; Sánchez-Muñoz, Diego; Núñez-Roldan, Antonio; Aguilar-Reina, José // American Journal of Gastroenterology;Jul2003, Vol. 98 Issue 7, p1621 

    : ObjectiveThe aim of this study was to assess the influence of host genetic factors on response to combination therapy for chronic hepatitis C infection.: MethodsPatients with biopsy-proved chronic hepatitis C infection were treated with interferon alone (n = 143) or combined therapy of...

  • Interferon-α-2b Plus Ribavirin: A Review of its Use in the Management of Chronic Hepatitis C. Scott, L.J.; Perry, C.M. // Drugs;2002, Vol. 62 Issue 3, p507 

    Relatively few patients (≤20%) with chronic hepatitis C achieve a sustained virological response after interferon-α monotherapy. Hence, alternative treatment strategies such as the addition of the broad spectrum antiviral agent ribavirin to interferon-α-2b have been investigated....

  • Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Tod, Michel; Farcy-Afif, Muriel; Stocco, Jeanick; Boyer, Nathalie; Bouton, Valérie; Sinè'gre, Martine; Marcellin, Patrick; Bouton, Valérie; Sinègre, Martine // Clinical Pharmacokinetics;2005, Vol. 44 Issue 4, p417 

    Background: Interferon (IFN)-alpha and ribavirin combination therapy is the standard treatment for patients with chronic hepatitis C. However, ribavirin induces anaemia, especially by haemolysis, an adverse effect that is dose-limiting.Objectives: The aim of this study...

  • Treatment of chronic hepatitis C in a patient with Fanconi anaemia. Rogalska-Płońska, M; Parfieniuk-Kowerda, A; Łapiński, T W; Flisiak, R // Advances in Medical Sciences (De Gruyter Open);2011, Vol. 56 Issue 2, p366 

    Fanconi anaemia is a rare autosomal recessive disorder with progressive bone marrow failure and predisposition to malignancy. We report a case of a 26-year-old female patient with Fanconi anaemia and severe chronic active hepatitis C virus infection. Her past medical history included treatment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics